Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of the evolution of Th17 immune response in patients with rheumatoid arthritis treated with tocilizumab and after failure of other therapies [Etude de l'evolution de la reponse immunitaire Th17 chez des patients atteints de polyarthrite rhumatoide et traites par tocilizumab apres echec des autres therapies]

Trial Profile

Study of the evolution of Th17 immune response in patients with rheumatoid arthritis treated with tocilizumab and after failure of other therapies [Etude de l'evolution de la reponse immunitaire Th17 chez des patients atteints de polyarthrite rhumatoide et traites par tocilizumab apres echec des autres therapies]

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Jun 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics; Pharmacogenomic

Most Recent Events

  • 28 Jun 2012 Planned End Date changed to 31 Oct 2011.
  • 27 Jun 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top